Repeatability of fixed-luminance parameters of full-field electroretinography in patients with non-infectious uveitis

Abstract

Purpose : In the present case series, we evaluated the intra-visit repeatability of fixed-luminance parameters of full-field electroretinography (ffERG) in patients with non-infectious uveitis using Diopsys® Nova ffERG.

Methods : A total of 14 patients (28 eyes) with non-infectious uveitis at a tertiary hospital from September 2021 to October 2021 were enrolled. Fixed-luminance flicker ERG testing was performed using Diopsys® Nova ffERG three times consecutively according to standard acquisition guidelines of Diopsys® Nova ffERG. Repeatability of three parameters (magnitude, phase, and latency) was assessed using intra-class correlation coefficients (ICC).

Results : Mean age of the patients was 45.7±20.9 (range, 12-71) years, and 7 (50%) were female. Uveitis was anterior, intermediate, posterior, and panuveitis in four, one, six, and three patients, respectively. Underlying diagnoses were multifocal choroiditis and panuveitis (%7.1), punctate inner choroidopathy (%7.1), and idiopathic (%85.7). Mean magnitude (M) measurements were M1=11.06±5.7 μm; M2=10.90±5.5 μm; M3=10.67±5.2 μm. Mean phase (P) measurements were P1=305.73°±43, P2=305.40°±44.4, P3=304.94°±45.5. Mean latency (L) measurements were L1=36.36±3.9 ms, L2=36.51±3.9 ms, L3=36.41±3.9 ms. ICC value using the single measures method was 0.977 (p<0,0001), 0.981 (p<0.0001), and 0.979 (p<0.0001) for the magnitude, phase, and latency parameters, respectively. Similarly, ICC value using the average measures method was 0.982 (p<0.0001), 0.993 (p<0.0001), and 0.993 (p<0,0001) for the magnitude, phase, and latency parameters, respectively.

Conclusions : Repeatability of fixed luminance parameters of full-field flicker using Diopsys® Nova device, including magnitude, phase, and latency was significantly excellent. Thus, fixed-luminance flicker ERG testing (Diopsys® Nova ffERG) may be helpful in the assessment of patients with non-infectious uveitis.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.